Interim report Q2, 2024: Strong Technologies growth and improved margins

Second quarter

• Sales of SEK 941 (905) million, an increase of 4% in local currencies and 4% in SEK.
• Sales per region, in local currencies was -5% in APAC, +11% in EMEA and +5% in Americas.
• Sales growth per business area, in local currencies, was +3% in Consumables, +40% in Technologies and -7% in Genetics.
• Gross margin increased to 59.9% (55.8).
• Operating income before depreciation and amortisation (EBITDA) increased to SEK 327 (293) million, giving an EBITDA margin of 34.7% (32.4).
• Operating cash flow increased to SEK 236 million (211).
• Net income increased to SEK 143 (106) million, giving earnings per share of SEK 1.06 (0.78).
• Vitrolife Group acquired the distribution activities of medical devices from EMB, our Iberian distributor.
• Vitrolife Group acquired eFertility (STB Zorg B.V.).

First half year

• Sales of SEK 1,782 (1,759) million, an increase of 2% in local currencies and 1% in SEK.
• Sales per region, in local currencies was +6% in APAC, +4% in EMEA and -4% in Americas.
• Sales per business area, in local currencies was +8% in Consumables, +23% in Technologies and -10% in Genetics.
• Gross margin increased to 58.6% (56.3).
• Operating income before depreciation and amortisation (EBITDA) increased to SEK 600 (554) million, giving an EBITDA margin of 33.6% (31.5).
• Operating cash flow increased to SEK 434 million (372).
• Net income increased to SEK 258 (205) million, giving earnings per share of SEK 1.91 (1.52).
   

Gothenburg, July 17, 2024
VITROLIFE AB (publ)
Bronwyn Brophy O´Connor, CEO

This disclosure contains information that Vitrolife AB (publ) is obliged to make public pursuant to the Swedish Securities Markets Act (2007:528). The information was submitted for publication, through the agency of the contact person, on 17-07-2024 08:00 CET.